The authors identified three distinct molecular and proteomic phenotypes- BASQ-like, luminal, and mixed, each with differentially expressed SNPs. Similar to the aforementioned study by Faltas et al., these germline DNA variants have a rationale in the liquid biopsy setting and deserve further investigation throughout the spectrum of bladder cancer stage, grade, and response to therapy.
Presented by: Raquel Benitez Dorta, Predoctoral Researcher, Spanish National Cancer Research Centre, Madrid, Spain
Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.